Four-drug chemo before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stomach cancer that can be removed with surgery and is considered borderline resectable (removable with some difficulty).
- You have not had irinotecan or irinotecan liposome chemotherapy before.
- You have no active, uncontrolled infections (like HIV, hepatitis B or C).
- You have no serious heart or lung disease, and your blood counts, liver and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.